Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947–1964: The Nurses’ Health Study II, a prospective cohort study
Open Access
- 17 December 2020
- journal article
- research article
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 36 (8) , 827-839
Abstract
Oral contraceptives (OCs) have been associated with long-term lower endometrial cancer risk; relatively little is known about associations with more recent OC formulations and associations with longer-term risk. A total of 107,069 women from the Nurses’ Health Study II recalled OC use from age 13 to baseline (1989); biennial questionnaires updated data on OC use until 2009. OCs were classified by estrogen and progestin type, dose, and potency based on reported brand. 864 incident endometrial cancer cases were identified through 2017. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals [95% CI] for the association of OC use with endometrial cancer risk. OC use was associated with lower endometrial cancer risk (ever use, HR 0.77 [95% CI 0.65–0.91]; >10 years of use, 0.43 [0.32–0.58] vs. never OC use). Inverse associations for duration were evident regardless of time since last use. Longer durations (> 5 years) of ethinyl estradiol (0.52 [0.41–0.67]) and second-generation progestins (0.43 [0.30–0.61]), both versus never use, were more strongly associated with lower risk than mestranol (0.66 [0.50–0.88], p-het = 0.01) and first-generation progestins (0.62 [0.49–0.78], p-het = 0.03). Inverse associations were generally observed for cross-classified cumulative average estrogen and progestin dose and potency (< vs. ≥ median; ever use vs. never OC use), with the exception of high estrogen and low progestin dose. OCs were associated with lower endometrial cancer risk, independent of time since last use. Use of ethinyl estradiol and second-generation progestins were more strongly inversely associated with risk compared with older formulations.Keywords
Funding Information
- National Institutes of Health (P01 CA87969)
- National Institutes of Health (U01 CA176726)
- Deutsches Krebsforschungszentrum (DKFZ)
This publication has 44 references indexed in Scilit:
- Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC)Endocrine-Related Cancer, 2008
- A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial CancerCancer Epidemiology, Biomarkers & Prevention, 2008
- Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception studyBMJ, 2007
- Progestin and estrogen potency of combination oral contraceptives and endometrial cancer riskGynecologic Oncology, 2006
- Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004British Journal of Cancer, 2006
- Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal womenInternational Journal of Cancer, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA)Cancer Causes & Control, 1994
- Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinomaInternational Journal of Cancer, 1991
- Flexible regression models with cubic splinesStatistics in Medicine, 1989